http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 06 Oct 2026 07:45:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Compugen+%28CGEN%29+Reiterated+at+Buy+by+Stifel+After+Overview+of+COM701+Trial/27151941.html <p>Stifel analyst Stephen Willey reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).</p><p>The analyst commented, "We’re reiterating our Buy-rating on CGEN shares following management’s virtual investor event intended to provide a KOLfacilitated overview of the ongoing MAIA-ovarian trial (COM701 vs. placebo as maintenance therapy in 2L/3L PSOC) and a reveal of the expanded UnigenX discovery platform to facilitate the discovery of novel tumor-associated antigens (TAAs). Management continues to guide to a 1Q27 disclosure of interim mPFS data from Sub-study 1 of the MAIA-ovarian trial, and we believe our visibility into this data remains admittedly limited given the http://www.streetinsider.com/Analyst+Comments/Compugen+%28CGEN%29+Reiterated+at+Buy+by+Stifel+After+Overview+of+COM701+Trial/27151941.html Tue, 06 Oct 2026 07:45:15 -0400 CGEN http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+a+Fireside+Chat+at+the+H.C.+Wainwright+3rd+Annual+AI+Based+Drug+Discovery+%26amp%3B+Development+Conference/27151636.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, ISRAEL</location></span>, <span class="legendSpanClass"><chron>Oct. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C. Wainwright 3^rd Annual <span>AI Based Drug Discovery &amp; Development Conference</span>, being held virtually on <chron>October 8-9, 2026</chron>.</p> http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+a+Fireside+Chat+at+the+H.C.+Wainwright+3rd+Annual+AI+Based+Drug+Discovery+%26amp%3B+Development+Conference/27151636.html Tue, 06 Oct 2026 07:00:00 -0400 CGEN http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+a+Fireside+Chat+at+the+H.C.+Wainwright+3rd+Annual+AI+Based+Drug+Discovery+%26amp%3B+Development+Conference/27151636.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, ISRAEL</location></span>, <span class="legendSpanClass"><chron>Oct. 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C. Wainwright 3^rd Annual <span>AI Based Drug Discovery &amp; Development Conference</span>, being held virtually on <chron>October 8-9, 2026</chron>.</p> http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+a+Fireside+Chat+at+the+H.C.+Wainwright+3rd+Annual+AI+Based+Drug+Discovery+%26amp%3B+Development+Conference/27151636.html Tue, 06 Oct 2026 07:00:00 -0400 CGEN http://www.streetinsider.com/Press+Releases/Compugen+to+Host+Virtual+KOL+Event+on+COM701+in+Ovarian+Cancer+%26amp%3B+Unigen%E2%84%A2+Platform+Update+on+October+5%2C+2026/27087331.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced it will host a virtual key opinion leader (KOL) event on <chron>Monday, October 5, 2026</chron> at <chron>8:00 AM ET</chron> featuring <person>Oladapo Yeku</person>, M.D., Ph.D., FACP (<span value="ACORN:3595432114" idsrc="xmltag.org" >Harvard Medical School</span>, <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span>), who will join company management to discuss COM701 http://www.streetinsider.com/Press+Releases/Compugen+to+Host+Virtual+KOL+Event+on+COM701+in+Ovarian+Cancer+%26amp%3B+Unigen%E2%84%A2+Platform+Update+on+October+5%2C+2026/27087331.html Tue, 22 Sep 2026 07:00:00 -0400 CGEN http://www.streetinsider.com/PRNewswire/Compugen+to+Host+Virtual+KOL+Event+on+COM701+in+Ovarian+Cancer+%26amp%3B+Unigen%E2%84%A2+Platform+Update+on+October+5%2C+2026/27087331.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced it will host a virtual key opinion leader (KOL) event on <chron>Monday, October 5, 2026</chron> at <chron>8:00 AM ET</chron> featuring <person>Oladapo Yeku</person>, M.D., Ph.D., FACP (<span value="ACORN:3595432114" idsrc="xmltag.org" >Harvard Medical School</span>, <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span>), who will join company management to discuss COM701 http://www.streetinsider.com/PRNewswire/Compugen+to+Host+Virtual+KOL+Event+on+COM701+in+Ovarian+Cancer+%26amp%3B+Unigen%E2%84%A2+Platform+Update+on+October+5%2C+2026/27087331.html Tue, 22 Sep 2026 07:00:00 -0400 CGEN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+Sep+10/27048369.html si-local-file:///var/storage/secattach/20260910/27048369.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+Sep+10/27048369.html Thu, 10 Sep 2026 16:05:00 -0400 CGEN http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150